TScan Therapeutics Ownership | Who Owns TScan Therapeutics?

Overview Forecast RevenueFinancials Chart

TScan Therapeutics Ownership Summary

TScan Therapeutics is owned by 30.95% institutional investors, 0.24% insiders, and 68.81% retail investors. Blackrock is the largest institutional shareholder, holding 4.70% of TCRX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.42% of its assets in TScan Therapeutics shares.

TCRX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	TScan Therapeutics	30.95%	0.24%	68.81%
Sector	Healthcare Stocks	279.18%	10.62%	-189.80%
Industry	Biotech Stocks	63.96%	10.74%	25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	4.46M	4.70%	$26.10M
Lynx1 capital management lp	5.36M	4.51%	$16.29M
Ecor1 capital	5.00M	4.21%	$15.20M
Blackrock funding, inc. /de	4.96M	4.18%	$15.08M
Adage capital partners gp	3.50M	2.95%	$10.64M
Bvf inc/il	2.99M	2.52%	$9.09M
Baker bros. advisors lp	2.78M	2.35%	$8.47M
Vanguard group	2.38M	2.01%	$7.24M
Propel bio management	2.09M	1.76%	$6.34M
Checkpoint capital	1.76M	1.48%	$5.34M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Dc funds, lp	630.00K	53.75%	$1.92M
Propel bio management	2.09M	6.30%	$6.34M
Lynx1 capital management lp	5.36M	6.11%	$16.29M
Checkpoint capital	1.76M	2.72%	$5.34M
Ecor1 capital	5.00M	0.57%	$15.20M
Bvf inc/il	2.99M	0.31%	$9.09M
Deer management	1.25M	0.30%	$3.79M
Alphabet	1.08M	0.19%	$3.27M
Dc investments management	35.56K	0.18%	$208.04K
Simplify asset management	1.05M	0.16%	$3.18M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	4.46M	0.00%	2.76M
Checkpoint capital	1.76M	2.72%	930.65K
Abrdn	883.70K	0.01%	512.05K
State street	608.09K	0.00%	473.08K
Blackrock funding, inc. /de	4.96M	0.00%	328.82K

Top Sellers

Holder	Shares	% Assets	Change
Great point partners	-	-	-1.02M
Adage capital partners gp	3.50M	0.02%	-900.00K
Stempoint capital lp	-	-	-860.95K
Paradigm biocapital advisors lp	-	-	-353.89K
Alpine global management	-	-	-137.49K

New Positions

Holder	Shares	% Assets	Change	Value
Tang capital management	117.85K	0.02%	117.85K	$358.25K
Bnp paribas arbitrage, snc	65.14K	0.00%	65.14K	$198.02K
Proshare advisors	13.14K	0.00%	13.14K	$39.95K
Prudential financial	10.41K	-	10.41K	$31.66K
China universal asset management	10.41K	0.00%	10.41K	$31.65K

Sold Out

Holder	Change
Federated hermes	-56.00
Gamma investing	-142.00
Macquarie group	-1.05K
Us bancorp \de\	-2.27K
Lazard asset management	-2.55K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	92	4.55%	40,135,892	-3.36%	30	2.53%	50	6.38%	19	18.75%
Dec 31, 2024	27	-68.60%	11,233,656	-73.15%	9	0.76%	13	-71.11%	5	-68.75%
Sep 30, 2024	86	10.26%	41,835,445	0.96%	35	1.85%	45	-8.16%	16	23.08%
Jun 30, 2024	78	18.18%	41,438,662	20.84%	43	1.60%	49	25.64%	13	44.44%
Mar 31, 2024	66	22.22%	34,293,057	7.46%	52	4.62%	39	14.71%	9	80.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	1.37M	2.42%	-
Simplify Propel Opportunities ETF	1.05M	1.85%	-
BlackRock Health Sciences Term Trust	1.05M	1.85%	-
iShares Russell 2000 ETF	951.51K	1.68%	465.00
Vanguard Institutional Extnd Mkt Idx Tr	706.08K	1.25%	33.02K
BlackRock Health Sciences Opps Inv A	650.52K	1.15%	-
Invesco Dorsey Wright SmallCap Momt ETF	475.53K	0.90%	-
abrdn Healthcare Investors	498.01K	0.88%	-
abrdn Life Sciences Investors	393.44K	0.70%	-
Fidelity Small Cap Index	379.31K	0.67%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 19, 2025	Lynx1 Capital Management LP	-	Buy	$1.67M
May 20, 2025	Lynx1 Capital Management LP	-	Buy	$1.44M
Dec 26, 2024	Lynx1 Capital Management LP	-	Buy	$750.00
Dec 13, 2024	Lynx1 Capital Management LP	-	Buy	$290.14K
Dec 12, 2024	Lynx1 Capital Management LP	-	Buy	$95.63K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	2	-
2025 Q1	-	-
2024 Q4	4	-
2024 Q3	3	1
2024 Q2	3	-

TCRX Ownership FAQ

Who Owns TScan Therapeutics?

TScan Therapeutics shareholders are primarily institutional investors at 30.95%, followed by 0.24% insiders and 68.81% retail investors. The average institutional ownership in TScan Therapeutics's industry, Biotech Stocks , is 63.96%, which TScan Therapeutics falls below.

Who owns the most shares of TScan Therapeutics?

TScan Therapeutics’s largest shareholders are Blackrock (4.46M shares, 4.70%), Lynx1 capital management lp (5.36M shares, 4.51%), and Ecor1 capital (5M shares, 4.21%). Together, they hold 13.43% of TScan Therapeutics’s total shares outstanding.

Does Blackrock own TScan Therapeutics?

Yes, BlackRock owns 4.70% of TScan Therapeutics, totaling 4.46M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.1M$. In the last quarter, BlackRock increased its holdings by 2.76M shares, a 162.61% change.

Who is TScan Therapeutics’s biggest shareholder by percentage of total assets invested?

Dc funds, lp is TScan Therapeutics’s biggest shareholder by percentage of total assets invested, with 53.75% of its assets in 630K TScan Therapeutics shares, valued at 1.92M$.

Who is the top mutual fund holder of TScan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of TScan Therapeutics shares, with 2.42% of its total shares outstanding invested in 1.37M TScan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools